Financial News

Financial Report: Allergan

U.S. Specialized Therapeutics revenues down 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan 1Q Revenues: $3.6 billion (-2%) 1Q Loss: $2.4 billion (loss of $284 million 1Q18) Comments: U.S. Specialized Therapeutics revenues were $1.5 billion in the quarter, down 2%. BOTOX Therapeutic, BOTOX Cosmetic and JUVÉDERM Collection growth was partially offset by a decline in CoolSculpting sales, lower RESTASIS revenues due to lower net pricing, as well as the divestiture of the Company’s Medical Dermatology business on September 2018. BOTOX Therapeutic sales in the quarter were...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters